Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma

Nicox announced an FDA PDUFA date of April 30, 2027 for its NCX 470 glaucoma NDA review, setting a clear regulatory timeline. The company also noted that two NDAs have been filed in major markets with commercial partners in place for expected launches from H2 2027 onward, and referenced an upcoming milestone payment due (amount not provided in the excerpt). Overall, the update is directionally positive but not sufficient on its own to imply a major earnings or valuation shift.